A new study from Danish researchers finds that high-dose flu vaccines reduced the incidence of pneumonia- and influenza-related hospitalization (P&I), but there was no difference in death rates between recipients of high-dose and standard-dose vaccines. The study is published in the Journal of Infection.
High-dose influenza vaccine (HD-IV), which contains four times as much hemagglutinin as standard-dose influenza vaccine (SD-IV), was designed to address lower protection from SD-IV in adults 65 and older.
Older adults are the most at risk for flu-related complications, and HD-IV has been demonstrated to induce higher antibody responses and significantly reduce the incidence of laboratory-confirmed influenza among older adults in multiple randomized trials, the authors said.
No difference in all-cause mortality
In the current study, the authors conducted a meta-analysis of all studies reporting outcomes of HD-IV compared to SD-IV regarding P&I hospitalization, all-cause hospitalization, and all-cause death in adults 65 and older over at least one flu season since 2009. Overall, their analysis included 105,685 participants with a mean age of 66 to 85 years.
HD-IV recipients demonstrated a P&I hospitalization rate of 0.8%, compared to 1.1% in the SD-IV group, for an overall vaccine efficacy of 23.5% (95% confidence interval [CI], 12.3% to 33.2%). For all-cause hospitalization, 14.1% of HD-IV recipients experienced hospitalization during the follow-up period, compared with 15.2% of SD-IV recipients, resulting in a vaccine efficacy of 7.3%.
The fixed-effects model indicated no difference in overall treatment effect between HD-IV and SD-IV regarding all-cause death.
“The fixed-effects model indicated no difference in overall treatment effect between HD-IV and SD-IV regarding all-cause death,” the authors said.